TITLE

THE INS & OUTS OF ESTROGEN

PUB. DATE
March 2001
SOURCE
Joe Weider's Muscle & Fitness;Mar2001, Vol. 62 Issue 3, p44
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Offers information on the decline of estrogen levels in younger women. Implication of a sudden drop in estrogen; Cause of the decline; How transdermal estrogen patches work; Side effects of transdermal estrogen patches.
ACCESSION #
4080861

 

Related Articles

  • Transdermal estrogen and prevention of osteoporosis. Filer, Wanda D.; Filer, Robert B. // American Family Physician;5/15/1994, Vol. 49 Issue 7, p1639 

    Examines the use of transdermal delivery of estrogen in patients receiving hormone replacement therapy for the prevention of osteoporosis. Transdermal delivery as an alternative to the oral route; Avoidance of the first-pass hepatic metabolism that occurs with oral agents; Contraindications to...

  • Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen. Lufkin, Edward G.; Wahner, Heinz W.; O'Fallon, William M.; Hodgson, Stephen F.; Kotowicz, Mark A.; Lane, Ann W.; Judd, Howard L.; Caplan, Robert H.; Riggs, B. Lawrence // Annals of Internal Medicine;7/1/92, Vol. 117 Issue 1, p1 

    Focuses on a study which evaluated the tolerance and effectiveness of transdermal estrogen for women with established postmenopausal osteoporosis and vertebral fractures. Patients and methods; Information on estrogen deficiency; Interventions.

  • Understanding Hormone Action: Does Route of Administration Matter? Berga, Sarah L. // OB/GYN Clinical Alert;Jul2007, Vol. 24 Issue 3, p20 

    The article comments on the findings of the Estrogen and Thromembolism Risk (ESTHER) Study Group on the risk of women taking estradiol and estrogen via oral and transdermal administration to thromboembolism. It notes that the study has only two cases and no controls took conjugated equine...

  • Minivelle Estrogen Patch.  // Nurse Practitioners Prescribing Reference;Spring2013, Vol. 20 Issue 1, pA-18 

    The article offers brief information on Minivelle for the treatment of moderate-to-severe vasomotor symptoms due to menopause from Noven.

  • Hormone patch for stronger bones.  // Joe Weider's Muscle & Fitness;Mar93, Vol. 54 Issue 3, p28 

    Reports on the effect of a transdermal patch that delivers estrogen through the skin on the bones of women with osteoporosis. Study of menopausal women with osteoporosis, conducted by E.G. Lufkin and colleagues.

  • Long-Term Transdermal Estrogen Therapy Improves Lipid Profile but Not Insulin Resistance in Healthy Postmenopausal Women. Lasco, Antonino; Alvaro, Santo; Frisina, Nicola; Di Benedetto, Antonino; Denuzzo, Giulia; Cucinotta, Domenico // Diabetes Care;Mar2000, Vol. 23 Issue 3, p422 

    Presents a study which determined at what extent a long-term treatment with transdermal estrogen can modify insulin sensitivity in postmenopausal women. Assessment of whether long-term estrogen-progestin therapy affects other major cardiovascular risk factors; Methodology; Results; Conclusions.

  • Premarin, Climara top list of select oral, transdermal osteoporosis prevention agents.  // Formulary;May99, Vol. 34 Issue 5, p388 

    Assesses formulary acceptance rates for osteoporosis prevention therapies in the United States. Increase in the acceptance of transdermal patch agent Climara; Domination of conjugated estrogen product Premarin in hospital and managed care organizations formularies; Addition of estrogen-receptor...

  • A Contemporary Review of Current and New Transdermal Hormonal Contraceptive Regimens. Shulman, Lee P. // Contemporary OB/GYN;Jun2013, Vol. 58 Issue 6, Special section p1 

    The article discusses some of the current as well as new transdermal hormonal contraceptive methods available along with advantages and disadvantages of each. Some of these include use of a transdermal contraceptive patch such as the Ortho Evra patch. Venous thromboembolism (VTE) has been found...

  • Testosterone for Low Libido. Speroff, Leon // OB/GYN Clinical Alert;Jan2009, Vol. 25 Issue 9, p67 

    A randomized, controlled trial concludes that transdermal testosterone at 300 μg per day modestly increases sexuality, but side effects are a concern.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics